**Star News, Laimei Pharmaceutical released a performance forecast, and it is expected that the attributable net profit loss for the whole year of 2023 will be 8 million yuan to 12 million yuan, an increase of 82 percent over the previous year54% to 8836%。
The announcement explained the reasons for the change in performance:
During the reporting period, the main reasons for the company's performance are as follows:
1) Holding subsidiaries out of the table.
During the reporting period, the company's original holding subsidiary, Sichuan Kangdesai Medical Technology Co., Ltd., hereinafter referred to as "Kangdesey") implemented equity incentives in the form of capital increase, and the company and other shareholders of Kangdesai waived their preemptive subscription rights. At the same time, Ding Ping, the legal representative and shareholder of Kangdesai, terminated the concerted action relationship with the company regarding Kangdesai. Together, the above events resulted in the loss of control of the Company and was no longer included in the Company's consolidated financial statements. For details, please refer to the "Announcement on the Holding Subsidiary Kangdesai Will No Longer Be Included in the Scope of Consolidated Statements" disclosed by the company on the Juchao Information Network.
According to the relevant provisions of the accounting standards, if an enterprise loses control of its original subsidiaries due to the disposal of part of the equity investment or other reasons, the remaining equity shall be remeasured at the fair value on the date of loss of control in the consolidated financial statements. After the release of the Kangdesai table, the company hired Chongqing Gemdale Real Estate Land Asset Appraisal *** to hold the company Kangdesel 31The fair value of 6275% of the equity was evaluated, and on January 30, 2024, the "Sichuan Kangdesai Medical Technology Involved in Chongqing Laimei Pharmaceutical Co., Ltd.*** for the purpose of financial reporting***316275% Equity Fair Value Appraisal Project Asset Appraisal Report [Heavy Gold Appraisal (2024) Zi No. 0009], the appraisal reference date is December 31, 2023, the market method is used for this evaluation, and the evaluation result is 11,918$940,000. According to the preliminary accounting of the company's financial department, the impact of the implementation of equity incentives and the removal of the company's consolidated financial statements from the implementation of equity incentives and the removal of the company's consolidated financial statements on the company's consolidated financial statements is: an increase in investment income of about 10,939180,000 yuan, an increase of about 2,628 yuan in administrative expenses$680,000, thereby increasing the total profit by about 8,310500,000 yuan, an increase in net profit attributable to shareholders of the listed company of about 8,360120,000 yuan (the above impact amount is unaudited, and the specific impact amount is subject to the final audit result).
2) Litigation matters.
According to the first-instance judgment of the company and its wholly-owned subsidiary, Chongqing Laimei Pharmaceutical*** and Changchun Haiyue Pharmaceutical Co., Ltd., on the purchase and sale contract dispute, the company's financial department has preliminarily calculated and confirmed that the non-operating expenses are 5,176160,000 yuan, affecting the net profit attributable to shareholders of the listed company of about -4,399740,000 yuan.
3) Policy implications.
Affected by the centralized procurement and provincial alliance centralized procurement policies, the company's revenue of some varieties decreased year-on-year, and the company accelerated R&D investment to enrich the company's product pipeline, which correspondingly affected operating profits.
4) The impact of non-recurring gains and losses on the company's net profit.
The Company expects the impact of non-recurring gains and losses on the Company's net profit for the reporting period to be approximately $65 million. 4. Other relevant instructions.
1) The company and its wholly-owned subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd. and Changchun Haiyue Pharmaceutical Co., Ltd., have been in the second instance of the purchase and sale contract dispute case, and as of now, the second-instance judgment has not been received, and there is great uncertainty, and the company cannot judge the final impact of this lawsuit on the financial situation for the time being.
2) The performance forecast data is the result of the preliminary calculation of the company's financial department, which has not been audited by the audit institution and is still uncertain. Specific figures for the 2023 annual results will be disclosed in detail in the Company's 2023 Annual Report. Investors are advised to make prudent decisions and pay attention to investment risks.
5. Documents for reference.
1) A statement from the board of directors on the company's 2023 annual performance forecast;
2) "Chongqing Laimei Pharmaceutical Co., Ltd. *** Sichuan Kangdesai Medical Technology Involved in the Financial Reporting Purpose***316275% Equity Fair Value Appraisal Project Asset Appraisal Report" [Heavy Gold Appraisal (2024) Zi No. 0009].
Chongqing Laimei Pharmaceutical Co., Ltd.*** Board of Directors January 30, 2024.
According to the third quarter report of Laimei Pharmaceutical in 2023, the company's main revenue is 64.5 billion yuan, down 389%；Net profit attributable to the parent company - 5451380,000 yuan, a year-on-year decrease of 4586%；Deduct non-net profit - 2782970,000 yuan, an increase of 6029%；Among them, in the third quarter of 2023, the company's single-quarter main revenue is 19.1 billion yuan, a year-on-year decrease of 2781%；The net profit attributable to the parent company in a single quarter was -45690,000 yuan, a year-on-year decrease of 10391%；Non-net profit deducted in a single quarter was -861430,000 yuan, an increase of 3361%；The debt ratio is 2724%, investment income 72260,000 yuan, financial expenses - 1818070,000 yuan, gross profit margin of 6927%。
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.